TLTian-Zhu Li

Tian-Zhu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tian-Zhu Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • An-Qi Wang

    Department of Biochemistry and Molecular Biology, Heilongjiang Bayi Agricultural University, Daqing, China

    1 shared publication
  • Bao Wu

    Department of Tissue and Embryology, College of Basic Medical Science, Chifeng University, Chifeng, China

    1 shared publication
  • Cheng-Hao Jin

    Department of Biochemistry and Molecular Biology, College of Life Science and Biotechnology, Heilongjiang Bayi Agricultural University, Daqing, China; Department of Food Science and Engineering, College of Food Science, Heilongjiang Bayi Agricultural University, Daqing, China; National Coarse Cereals Engineering Research Center, Daqing, China

    1 shared publication
  • Chun-Ying Bai

    Department of Molecular Biology, College of Basic Medical Science, Chifeng University, Chifeng, China

    1 shared publication
  • Cong-Ying Zhang

    Department of Pharmacy, College of Basic Medical Science, Chifeng University, Chifeng, China

    1 shared publication
  • Jing Zhou

    Department of Molecular Biology, College of Basic Medical Science, Chifeng University, Chifeng, China

    1 shared publication

Latest Publications

  • Open Access

    Sciadopitysin exerts anticancer effects on HepG2 hepatocellular carcinoma cells by regulating reactive oxygen species-mediated signaling pathways

    by Yan-Nan Li, Yun-Hong Xiu, Yan-Jun Tang, Jing-Long Cao, Wen-Shuang Hou, An-Qi Wang, Tian-Zhu Li, Cheng-Hao Jin

    Objectives: Sciadopitysin (SP) is a flavonoid in Ginkgo biloba that exhibits various pharmacological activities. This study aimed to investigate its antitumor effects and the underlying molecular mechanism of SP in hepatocellular carcinoma (HCC) cells. Methods: Network pharmacology was used for target prediction analysis. Cell Counting Kit-8 (CCK-8) assay was used to test the cell viability. Flow cytometry was used to test the cell cycle distribution, apoptosis status, and reactive oxygen species (ROS) levels. Transwell and wound-healing assay was used to test the migration effect of SP on HepG2 cells. Western Blot assay was used to test the expression levels of proteins. Results: Network pharmacology analysis results showed that the mitogen-activated protein kinase (MAPK) and other signaling pathways are involved in the SP anti-HCC biological process. CCK-8 assay results demonstrated that SP showed an obvious killing effect on three types of HCC cells and low cytotoxic effect on normal cells. Western Blot and flow cytometry results showed that SP regulated MAPK/signal transducer and activator of transcription 3 (STAT3)/nuclear factor kappa-B (NF-κB) signaling pathway to induce mitochondrion-dependent apoptosis in HepG2 cells. Additionally, SP can arrest the G0/G1 phase cell cycle via the protein kinase B (AKT)/p21/p27/cyclin-dependent kinase (CDK)/Cyclin signaling pathway. Wound healing and transwell assays showed that SP inhibited cell motility and invasion through the AKT/glycogen synthase kinase3β (GSK-3β)/vimentin/β-catenin signaling pathway. Conclusion: These findings demonstrated that SP induced mitochondrion-dependent apoptosis, arrested cell cycle in the G0/G1 phase, and inhibited cell migration by regulating the ROS-mediated signaling pathway in HepG2 cells. Thus, SP could serve as a therapeutic agent for the treatment of human HCC.


  • Open Access

    The Elk-3 target Abhd10 ameliorates hepatotoxic injury and fibrosis in alcoholic liver disease

    by Tian-Zhu Li, Chun-Ying Bai, Bao Wu, Cong-Ying Zhang, Siriguleng, Wen-Tao Wang, Tie-Wei Shi, Jing Zhou

    Alcoholic liver disease (ALD) and other forms of chronic hepatotoxic injury can lead to transforming growth factor β1 (TGFβ1)-induced hepatic fibrosis and compromised liver function, underscoring the need to develop novel treatments for these conditions. Herein, our analyses of liver tissue samples from severe alcoholic hepatitis (SAH) patients and two murine models of ALD reveals that the ALD phenotype was associated with upregulation of the transcription factor ETS domain-containing protein (ELK-3) and ELK-3 signaling activity coupled with downregulation of α/β hydrolase domain containing 10 (ABHD10) and upregulation of deactivating S-palmitoylation of the antioxidant protein Peroxiredoxin 5 (PRDX5). In vitro, we further demonstrate that ELK-3 can directly bind to the ABHD10 promoter to inhibit its transactivation. TGFβ1 and epidermal growth factor (EGF) signaling induce ABHD10 downregulation and PRDX5 S-palmitoylation via ELK-3. This ELK-3-mediated ABHD10 downregulation drives oxidative stress and disrupts mature hepatocyte function via enhancing S-palmitoylation of PRDX5’s Cys100 residue. In vivo, ectopic Abhd10 overexpression ameliorates liver damage in ALD model mice. Overall, these data suggest that the therapeutic targeting of the ABHD10-PRDX5 axis may represent a viable approach to treating ALD and other forms of hepatotoxicity.